Method of treatment and selection of patients benefiting from agomelatine based on eeg measurements
AssigneeAlto Neuroscience, Inc.
InventorsAmit ETKIN, Wei WU, Adam SAVITZ, Joshua JORDAN, Maimon ROSE, Akshay SUJATHA RAVINDRAN
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of agomelatine (or a prodrug or salt thereof) in the treatment of major depressive disorder or bipolar disorder, including the selection of patients who would most benefit from agomelatine.
Claims21
1-39. (canceled)
A method of treating major depressive disorder in a patient comprising administering to the patient a therapeutically effective amount of agomelatine or a pharmaceutically acceptable salt thereof, wherein the patient prior to initiation of agomelatine treatment exhibits high EEG sample entropy using low gamma frequency range (30-40 Hz) electroencephalography.
A method of treating major depressive disorder in a patient comprising:
- (a) analyzing one or more indicators of the responsiveness of the patient to agomelatine or a pharmaceutically acceptable salt thereof as a treatment, wherein the one or more indicators are selected from EEG measures of entropy or complexity, and any combination of any of the foregoing;
- and
- (b) administering to the patient an effective amount of agomelatine or a pharmaceutically acceptable salt thereof, where the patient is determined to be responsive to agomelatine based on the one or more indicators.
53-64. (canceled)
Dependencies are inferred from the claim text.